Morusin Induces TRAIL Sensitization by Regulating EGFR and DR5 in Human Glioblastoma Cells

Journal of Natural Products
Dain ParkSeok-Geun Lee

Abstract

Glioblastoma is one of the most malignant primary tumors, and the prognosis for glioblastoma patients remains poor. Tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL) is considered a promising anticancer agent due to its remarkable ability to selectively kill tumor cells. However, since many cancers are resistant to TRAIL, strategies to overcome resistance are required for the successful use of TRAIL in the clinic. In the present study, the potential of morusin as a TRAIL sensitizer in human glioblastoma cells was evaluated. Treatment with TRAIL or morusin alone showed weak cytotoxicity in human glioblastoma cells. However, combination treatment of TRAIL with morusin synergistically decreased cell viability and increased apoptosis compared with single treatment. Morusin induced expression of death receptor 5 (DR5), but not DR4 or decoy receptors (DcR1 and DcR2). Furthermore, morusin significantly decreased anti-apoptotic molecules survivin and XIAP. In addition, morusin reduced expression of EGFR and PDFGR as well as phosphorylation of STAT3, possibly mediating down-regulation of survivin and XIAP. Together these results suggest that morusin enhances TRAIL sensitivity in human glioblastoma cells through regulating ...Continue Reading

References

Apr 4, 1997·Science·G PanV M Dixit
Nov 25, 2003·Fitoterapia·Toshio FukaiHiroshi Sakagami
Apr 29, 2005·Current Drug Targets·Joan Albanell, Pere Gascón
Jan 7, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Tanya GritskoRichard Jove
Dec 6, 2006·Journal of Neuropathology and Experimental Neurology·Masahiro MizoguchiCatherine L Nutt
Oct 3, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Hui-Wen LoFrancis Ali-Osman
Oct 20, 2009·European Journal of Pharmacology·Peter A Holoch, Thomas S Griffith
Mar 24, 2010·The Journal of Cell Biology·Bernhard GillissenPeter T Daniel
Jan 20, 2011·Neoplasia : an International Journal for Oncology Research·Wen-Bin OuJonathan A Fletcher
Jul 18, 2012·Cancer Treatment Reviews·Lin-Tao JiaAn-Gang Yang
Aug 31, 2012·Experimental & Molecular Medicine·Ok Won SeoYoung Myeong Kim
Feb 6, 2013·Journal of Visualized Experiments : JoVE·Sebastian SchildgeChristian Schachtrup
Mar 5, 2013·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Lars Arne BergerDjordje Atanackovic
Mar 22, 2013·Journal of Pharmacological Sciences·Sang-Yoon ParkSeok-Geun Lee
Jul 13, 2013·Molecular and Cellular Biochemistry·Sojung ParkInki Kim
Jan 7, 2014·Biochimica Et Biophysica Acta·Kodappully Sivaraman SiveenAnupam Bishayee
Apr 1, 2013·Brain Tumor Research and Treatment·Kyu-Won JungHeon Yoo
Jun 10, 2014·Biochemical and Biophysical Research Communications·Fenglin ZangBaocun Sun
Jan 7, 2015·Nature Reviews. Clinical Oncology·David A Reardon, Patrick Y Wen
Apr 10, 2015·Nature Reviews. Cancer·Frank B FurnariPaul S Mischel
May 23, 2015·Journal of Cancer·Sofia LampakiPaul Zarogoulidis

❮ Previous
Next ❯

Citations

Aug 20, 2019·Journal of Materials Chemistry. B, Materials for Biology and Medicine·Srishti AgarwalD Sakthi Kumar
Feb 6, 2020·Planta medica·Ying GaoHanli Ruan
Sep 11, 2020·International Journal of Molecular Sciences·Dong Wook ChoiCheol Yong Choi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis